IRIS
CHIAPPINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.172
NA - Nord America 1.043
EU - Europa 464
SA - Sud America 416
AF - Africa 66
OC - Oceania 4
Totale 3.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 952
SG - Singapore 372
IT - Italia 336
BR - Brasile 306
CN - Cina 220
HK - Hong Kong 158
BD - Bangladesh 92
VN - Vietnam 83
IN - India 53
MX - Messico 46
AR - Argentina 36
CA - Canada 28
IQ - Iraq 28
FR - Francia 27
PK - Pakistan 20
EC - Ecuador 19
ID - Indonesia 16
TR - Turchia 16
CO - Colombia 15
PH - Filippine 15
UZ - Uzbekistan 15
DE - Germania 14
GB - Regno Unito 14
NL - Olanda 14
ZA - Sudafrica 14
MY - Malesia 13
RU - Federazione Russa 13
VE - Venezuela 13
JO - Giordania 12
SA - Arabia Saudita 12
CL - Cile 11
MA - Marocco 10
TN - Tunisia 10
KE - Kenya 8
PL - Polonia 8
NP - Nepal 7
PY - Paraguay 7
AL - Albania 6
OM - Oman 6
UA - Ucraina 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
JM - Giamaica 5
DZ - Algeria 4
ES - Italia 4
GH - Ghana 4
TH - Thailandia 4
AU - Australia 3
AZ - Azerbaigian 3
ET - Etiopia 3
KZ - Kazakistan 3
RO - Romania 3
TT - Trinidad e Tobago 3
DK - Danimarca 2
FI - Finlandia 2
GT - Guatemala 2
HR - Croazia 2
IE - Irlanda 2
IR - Iran 2
KG - Kirghizistan 2
KR - Corea 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
YE - Yemen 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GF - Guiana Francese 1
GN - Guinea 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MZ - Mozambico 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
Totale 3.164
Salva come PNG Salva come JPEG
Città #
San Jose 519
Singapore 208
Rome 167
Ashburn 156
Hong Kong 155
Beijing 120
Mexico City 40
Ho Chi Minh City 29
Santa Clara 29
Hanoi 23
Milan 21
Baghdad 14
São Paulo 14
Tashkent 13
Amman 10
Florence 10
Rio de Janeiro 10
Karachi 9
New York 9
Toronto 9
Caracas 8
Frankfurt am Main 8
Buffalo 7
Porto Alegre 7
Quito 7
Atlanta 6
Belo Horizonte 6
Brescia 6
Dhaka 6
Guayaquil 6
Johannesburg 6
Nairobi 6
Perugia 6
Aci Catena 5
Brasília 5
Casablanca 5
Chicago 5
Council Bluffs 5
Delhi 5
Jeddah 5
Kaithal 5
Kuala Lumpur 5
Los Angeles 5
Pittsburgh 5
Ribeirão Preto 5
Accra 4
Benevento 4
Cincinnati 4
Contagem 4
Cotia 4
Curitiba 4
Hamilton 4
Houston 4
Izmir 4
Manaus 4
Medellín 4
Montevideo 4
Muscat 4
Naples 4
Riyadh 4
Salvador 4
San Antonio 4
Santiago 4
Tirana 4
Tunis 4
Addis Ababa 3
Alexandria 3
Ankara 3
Baku 3
Baltimore 3
Betim 3
Brooklyn 3
Bucharest 3
Cairo 3
Da Nang 3
Decatur 3
Duque de Caxias 3
El Paso 3
Fortaleza 3
Guarujá 3
Guarulhos 3
Haiphong 3
Jacksonville 3
Jakarta 3
Kathmandu 3
Lahore 3
Madrid 3
Manila 3
Mumbai 3
Necochea 3
Palermo 3
Paranaque City 3
Parma 3
Philadelphia 3
Picos 3
Pune 3
San Diego 3
Sermoneta 3
The Bronx 3
Thái Nguyên 3
Totale 1.895
Salva come PNG Salva come JPEG
Nome #
Understanding the use of prescription and OTC drugs in obtaining highs and the pharmacist role in preventing abuse 172
Knowledge and use of over-the-counter drugs in Italy: an exploratory survey-based study in the general population 67
Evaluating craving in Alcohol Use Disorder: psychometric characteristics of the Craving Typology Questionnaire-15 (CTQ-15) 60
Le nuove sostanze psicoattive 54
Nuove frontiere nell'abuso di sostanze, psiconauti e internet 50
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study) 49
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases 47
New psychoactive substances and suicidality: A systematic review of the current literature 47
Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature 46
Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases 43
'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports 43
Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants 43
New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review 42
2876 – Glutamatergic strategies in the treatment of pathological gambling: a pilot study 41
The e-psychonaut drugs' psychopharmacology 40
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): An Analysis of Pharmacovigilance Databases 39
Utilizzo del pregabalin nel trattamento del gioco d'azzardo patologico: dati preliminari 39
Duration of untreated disorder and cannabis use: An observational study on a cohort of young italian patients experiencing psychotic experiences and dissociative symptoms 38
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data 37
Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice 36
A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's ‘suspected adverse drug reactions' database. Assessment of gabapentinoid misuse/dependence as reported to the EMA 36
‘Z-trip'? A comprehensive overview and and a case-series of Zolpidem misuse 36
A multidisciplinary approach for addiction treatment in an Italian day hospital service: a therapy model and its goals 35
Assessing The 2004-2018 Fentanyl Misusing Issues Reported To An International Range Of Adverse Reporting Systems 35
Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports 35
Beyond the purple drank. Study of promethazine abuse according to the Eurovigilance dataset 35
Beyond the ‘purple drank’. Study of promethazine abuse according to the European Medicines Agency (EMA) Adverse Drug Reactions (ADR) reports 34
Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel 34
Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review 33
Evaluation of an italian sample of gamblers with dannon ainhold gambling scale: preliminary study 33
Gestione dei pazienti con depressione resistente al trattamento in comorbilità con il disturbo da uso di sostanze: sicurezza ed efficacia dell'esketamina in un sottocampione di pazienti dello studio REAL-ESK 33
Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study 33
Climate change, biodiversity loss and mental health: a global perspective 33
Behavioural changes in cocaine dependent patients after group-therapy 33
Recreational Drug Misuse and Its Potential Contribution to Male Fertility Levels' Decline: A Narrative Review 33
What about “pharming”? Issues regarding the misuse of prescription and over-the-counter drugs 32
Methoxetamine: An Analogue of Ketamine 32
High-Risk Gaming Is Associated with Frequent Substance Use: An Exploratory Survey among Young Adults 32
β-2 agonists as misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency (EMA) Pharmacovigilance Database Reports. 32
Opioid painkiller dependence in a sample of elderly medical inpatients 32
New/emerging psychoactive substances and associated psychopathological consequences. 32
COVID-19: The hidden impact on mental health and drug addiction 32
ARE Z-DRUGS SAFE? STUDY OF THEIR MISUSE, ABUSE AND DEPENDENCE ACCORDING TO THE EUROPEAN MEDICINES AGENCY (EMA) PHARMACOVIGILANCE DATABASE. 32
Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. 31
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset 31
Addiction: a therapeutic model for the restructuring of identity 31
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group 31
The role of novel psychoactive substances (NPS) in mental health care of young people: a systematic review 31
Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years 31
Relationship between impulsivity, mood disorders and personality traits in a sample of pathological gamblers 31
Age in Pathological Gambling: Correlations with Personality and Psychiatric Comorbidity. 31
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression 30
Cannabidiol (CBD) Use in Psychiatric Disorders: a Systematic Review 30
Misuse of Anticholinergic Medications: A Systematic Review 30
Pharmacovigilance signals of the opioid epidemic over 10 years: an analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS) 30
Brexpiprazole as a new approach of treatment in somatization disorder 30
Psychobiological, medical, and psychiatric implications of new/novel psychoactive substance (NPS) use 30
Pregabalin treatment in pathological gambling: a preliminary study 30
Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database 29
Psychopathologic aspects of obesity: Psychodiagnostic evaluations of bariatric surgery applicants 29
There is a potential of misuse for venlafaxine and bupropion? 29
Substance-Use Disorders and Violence 29
The bridge between classical and ‘synthetic'/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective 28
Mobile phone use during adolescence: a new addiction? 28
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study 28
The opioid epidemic over the past 10 years: pharmacovigilance signals from the European Medicines Agency (EMA) and the FDA Adverse Event Reporting System (FAERS) 28
Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction 28
Validation of a diagnostic questionnaire based on DSM-IV criteria for gambling. 28
Psychosocial risk factors for postpartum depression: a descriptive sample of pregnants 28
Loperamide diversion and abuse: assessment of its non-medical use through the analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports 28
Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History 27
The benzydamine experience: a systematic review of benzydamine abuse 27
Pregabalin: a range of misuse-related unanswered questions 26
Alprazolam-related deaths in Scotland, 2004-2020 26
The Unregulated Psychoactive Compound: ‘Benzo Fury' 26
Efficacy of psychosocial and psychological interventions in addition to drug therapy to improve global functioning of inpatients with schizophrenia spectrum and mood disorders: a real-world observational study 26
Online Gambling, Impulsivity and Personality Traits: an Italian Sample 26
Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward 26
Ibogaine/Noribogaine in the treatment of Substance Use Disorders: a systematic review and Meta-analysis of side effects 25
Efficacy of Noninvasive Brain Stimulation on Borderline Personality Disorder Core Symptoms: A Systematic Review 25
Compulsiveness dimension in a case of pathological gambling 25
NPS stimulants 25
Misuse and Abuse of Prescription Drugs in Custodial Settings 25
Behavioural Addictions In Adolescence: Findings From An Italian Survey 25
New psychoactive substances (NPS), psychedelic experiences, and dissociation; clinical and clinical pharmacological issues. 24
The misuse of prescription drugs in the digital era: pros and cons 24
Special M related fatalities in the UK. 23
An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR) 23
An Update on Psychoactive Substances: Pharmacology and Toxicology Issues 23
Cannabis: evidenze epidemiologiche, cliniche e terapeutiche 22
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy 21
Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports 21
Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database 20
To bridge or not to bridge: Moral Judgement in Cocaine Use Disorders, a case-control study on human morality. 19
Totale 3.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.233
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.233
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20241 0 0 0 0 0 0 0 0 0 0 0 1
2024/2025777 21 99 3 0 22 12 61 128 56 38 188 149
2025/20262.339 122 25 154 158 243 169 191 111 573 304 144 145
2026/202761 61 0 0 0 0 0 0 0 0 0 0 0
Totale 3.178